Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/39313
Conference/Presentation Title: Hypothyroidism in pregnancy; implications of the 2016 updated guidelines for the Monash Health Endocrine in pregnancy clinic.
Authors: Allan C.;Yang J. ;Atkins E.
Monash Health Department(s): Endocrinology
Institution: (Atkins, Allan, Yang) Department of Endocrinology, Monash Health, Clayton, VIC, Australia (Allan, Yang) Hudson Institute of Medical Research, Melbourne, VIC, Australia
Presentation/Conference Date: 9-Feb-2017
Copyright year: 2017
Publisher: Blackwell Publishing Ltd
Publication information: Clinical Endocrinology. Conference: Endocrine Society of Australia Annual Scientific Meeting 2016. Gold Coast, QLD Australia. 86 (Supplement 1) (pp 40), 2017. Date of Publication: January 2017.
Abstract: Background: Pregnancy has a significant impact on the thyroid gland with alterations in thyroid stimulating hormone (TSH) and thyroid hormone levels. New guidelines proposed by the American Thyroid Association1 suggest that thyroxine replacement is not required in pregnant women with TSH <4mIU/L, and negative thyroid peroxidase (TPO) and thyroglobulin (Tg) autoantibodies. Aim(s): 1. To assess the range of TSH values and autoantibody status of women with newly diagnosed hypothyroidism in pregnancy 2. To identify the proportion of women in whom thyroxine treatment will no longer be recommended Methods An audit of women reviewed in the Monash Health Endocrine in Pregnancy Clinic between March 2012 and December 2015 was performed. Data collected included gestational history, plurality of pregnancy, past history of thyroid disease, thyroid function tests (TFTs) and antibody status. Result(s): Two hundred and eighty-nine women were reviewed for hypothyroidism; 148 (51.2%) of these women were newly diagnosed with hypothyroidism in pregnancy, currently defined by TSH > 2.5 mIU/L in the first trimester, with a mean gestation at first TFTs of 10.8 weeks. All were confirmed singleton pregnancies. Amongst these women, 49 (33.1%) had an initial TSH measurement of 2.5-4.0mIU/L, 80 (54.1%) had a TSH of 4.1-9.99 mIU/L and 19 (12.8%) had a TSH >= 10.0 mIU. Of those with TSH values of 2.5-4.0 mIU/L, 17 (35%) were identified as positive for either TPO or Tg antibodies, 26 (53%) were both TPO and Tg antibody negative with the remaining 6 patients' antibody status unknown. Conclusion(s): New guidelines proposed by the American Thyroid Association suggest that thyroxine during pregnancy is not required in women with a TSH <4 mIU/L and negative thyroid autoantibodies. Based on these recommendations, approximately 20% of women overall, but 50% of those with TSH 2.5-4.0 mIU/L, currently referred to our service may not require thyroxine or specialist Endocrinologist review during pregnancy.
Conference Start Date: 2016-08-21
Conference End Date: 2016-08-24
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/cen.13259
ISSN: 1365-2265
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/39313
Type: Conference Abstract
Subjects: female
*first trimester pregnancy
*hospital
human
*hypothyroidism
major clinical study
male
*practice guideline
thyroid function test
endogenous compound
thrombopoietin
thyroglobulin antibody
thyroid antibody
thyrotropin
thyroxine
controlled study
clinical trial
diagnosis
drug therapy
*endocrine system
endocrinologist
thyroid function test
human
*hospital
*first trimester pregnancy
female
endocrinologist
*endocrine system
drug therapy
diagnosis
*hypothyroidism
major clinical study
male
*practice guideline
controlled study
clinical trial
Appears in Collections:Conferences

Show full item record

Page view(s)

28
checked on Sep 2, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.